Skip to content

Eli Lilly LLY Income taxes payable – long-term

Income taxes payable – long-term at other companies

Cencora logo
CencoraCOR
$352.77M+27.0%

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.07T+51.7%
Enterprise value$1.11T+49.3%
P/E42.3×-8.8×
P/S14.8×+1.6×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:AccruedIncomeTaxesNoncurrent.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's income taxes payable – long-term.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's income taxes payable – long-term?
Eli Lilly (LLY) reported income taxes payable – long-term of $5.29B in Q1 2026.
How has Eli Lilly's income taxes payable – long-term changed year-over-year?
Eli Lilly's income taxes payable – long-term decreased by 1.5% year-over-year, from $5.37B to $5.29B.
What is the long-term trend for Eli Lilly's income taxes payable – long-term?
Over 5 years (2020 to 2025), Eli Lilly's income taxes payable – long-term has grown at a 8.9% compound annual growth rate (CAGR), from $3.84B to $5.88B.